During the past decade, Baylor Cancer Hospital conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Baylor Cancer Hospital" are "Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma" (1 trials) and "Relapsed/Refractory Mantle Cell Lymphoma" (1 trials). Many other conditions were trialed in "Baylor Cancer Hospital" in a lesser frequency.

Most popular intervention types in "Baylor Cancer Hospital" are "Biological" (2 trials) and "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (2 trials), "Fludarabine" (2 trials), "Brexucabtagene autoleucel" (1 trials) and "brexucabtagene autoleucel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Baylor Cancer Hospital" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Baylor Cancer Hospital". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Baylor Cancer Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Baylor Cancer Hospital, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".